Aug 25 (Reuters) – Recent clinical trial results are likely
to lead doctors to treat more patients who have a common form of
lung cancer with a Merck drug at the expense of a
Bristol-Myers Squibb…
The post Lung cancer doctors eye Merck’s Keytruda over Bristol’s Opdivo appeared first on NASDAQ.